Incidence, risk factors for active tuberculosis infection and changes of IGRA in patients with Takayasu arteritis: a prospective cohort study
There is limited evidence to support the association between tuberculosis (TB) and the occurrence of Takayasu arteritis (TAK). To investigate the incidence of active TB (ATB) in TAK and explore the impact of anti-rheumatic therapy on the occurrence of ATB or reactivation of Latent TB infection (LTBI...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2024.2302099 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850111887552806912 |
|---|---|
| author | Zhao Peng Jing Li Zhan Rong Yangzhong Zhou Yanhong Wang Ying Wang Guizhi Zhang Yunjiao Yang Xinping Tian Xiaofeng Zeng |
| author_facet | Zhao Peng Jing Li Zhan Rong Yangzhong Zhou Yanhong Wang Ying Wang Guizhi Zhang Yunjiao Yang Xinping Tian Xiaofeng Zeng |
| author_sort | Zhao Peng |
| collection | DOAJ |
| description | There is limited evidence to support the association between tuberculosis (TB) and the occurrence of Takayasu arteritis (TAK). To investigate the incidence of active TB (ATB) in TAK and explore the impact of anti-rheumatic therapy on the occurrence of ATB or reactivation of Latent TB infection (LTBI) and their effect on interferon-γ release assay (IGRA) results, we conducted a prospective study based on the Chinese Registry for Systemic Vasculitis cohort. The standard incidence ratio (SIR) was calculated and stratified by age. Kaplan–Meier analysis was used to determine the effect of variables on ATB or LTBI reactivation in patients with TAK. Data from 825 patients with TAK in the registry were analysed. During a median follow-up of 5 years, 5 patients developed ATB with a crude incidence of 154 (95%CI:57–381) person-years/100,000. The SIR was 5.59 (95%CI:1.81–13.04). Glucocorticoids and conventional disease-modifying anti-rheumatic drugs (cDMARDs) did not increase the risk of ATB or LTBI reactivation (P > 0.05). However, the use of tumour necrosis factor inhibitor (TNFi) increased the risk of ATB in patients with LTBI (P < 0.001). Furthermore, the value of the IGRA assay decreased after treatment (P < 0.05). In conclusion, the incidence of TB infection is markedly increased in patients with TAK and patients with TAK are at high risk of developing ATB. Treatment with glucocorticoids and cDMARDs does not significantly increase the risk for ATB in patients with TAK. Moreover, IGRA may have limited effectiveness in monitoring ATB infection or LTBI reactivation in patients with TAK. |
| format | Article |
| id | doaj-art-11ec6e694cd74be9996685ec191e82a5 |
| institution | OA Journals |
| issn | 2222-1751 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj-art-11ec6e694cd74be9996685ec191e82a52025-08-20T02:37:32ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512024-12-0113110.1080/22221751.2024.2302099Incidence, risk factors for active tuberculosis infection and changes of IGRA in patients with Takayasu arteritis: a prospective cohort studyZhao Peng0Jing Li1Zhan Rong2Yangzhong Zhou3Yanhong Wang4Ying Wang5Guizhi Zhang6Yunjiao Yang7Xinping Tian8Xiaofeng Zeng9Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, People’s Republic of ChinaDepartment of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, People’s Republic of ChinaSchool of Medicine, University of California San Diego, San Diego, CA, USADepartment of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, People’s Republic of ChinaDepartment of Epidemiology and Biostatistics, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences & School of Basic Medicine Peking Union Medical College, Beijing, People’s Republic of ChinaDepartment of Epidemiology and Biostatistics, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences & School of Basic Medicine Peking Union Medical College, Beijing, People’s Republic of ChinaDepartment of Rheumatology and Immunology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, People’s Republic of ChinaDepartment of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, People’s Republic of ChinaDepartment of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, People’s Republic of ChinaDepartment of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, People’s Republic of ChinaThere is limited evidence to support the association between tuberculosis (TB) and the occurrence of Takayasu arteritis (TAK). To investigate the incidence of active TB (ATB) in TAK and explore the impact of anti-rheumatic therapy on the occurrence of ATB or reactivation of Latent TB infection (LTBI) and their effect on interferon-γ release assay (IGRA) results, we conducted a prospective study based on the Chinese Registry for Systemic Vasculitis cohort. The standard incidence ratio (SIR) was calculated and stratified by age. Kaplan–Meier analysis was used to determine the effect of variables on ATB or LTBI reactivation in patients with TAK. Data from 825 patients with TAK in the registry were analysed. During a median follow-up of 5 years, 5 patients developed ATB with a crude incidence of 154 (95%CI:57–381) person-years/100,000. The SIR was 5.59 (95%CI:1.81–13.04). Glucocorticoids and conventional disease-modifying anti-rheumatic drugs (cDMARDs) did not increase the risk of ATB or LTBI reactivation (P > 0.05). However, the use of tumour necrosis factor inhibitor (TNFi) increased the risk of ATB in patients with LTBI (P < 0.001). Furthermore, the value of the IGRA assay decreased after treatment (P < 0.05). In conclusion, the incidence of TB infection is markedly increased in patients with TAK and patients with TAK are at high risk of developing ATB. Treatment with glucocorticoids and cDMARDs does not significantly increase the risk for ATB in patients with TAK. Moreover, IGRA may have limited effectiveness in monitoring ATB infection or LTBI reactivation in patients with TAK.https://www.tandfonline.com/doi/10.1080/22221751.2024.2302099Takayasu arteritistuberculosisstandard incidence ratiorisk factorsinterferon-γ release assay |
| spellingShingle | Zhao Peng Jing Li Zhan Rong Yangzhong Zhou Yanhong Wang Ying Wang Guizhi Zhang Yunjiao Yang Xinping Tian Xiaofeng Zeng Incidence, risk factors for active tuberculosis infection and changes of IGRA in patients with Takayasu arteritis: a prospective cohort study Emerging Microbes and Infections Takayasu arteritis tuberculosis standard incidence ratio risk factors interferon-γ release assay |
| title | Incidence, risk factors for active tuberculosis infection and changes of IGRA in patients with Takayasu arteritis: a prospective cohort study |
| title_full | Incidence, risk factors for active tuberculosis infection and changes of IGRA in patients with Takayasu arteritis: a prospective cohort study |
| title_fullStr | Incidence, risk factors for active tuberculosis infection and changes of IGRA in patients with Takayasu arteritis: a prospective cohort study |
| title_full_unstemmed | Incidence, risk factors for active tuberculosis infection and changes of IGRA in patients with Takayasu arteritis: a prospective cohort study |
| title_short | Incidence, risk factors for active tuberculosis infection and changes of IGRA in patients with Takayasu arteritis: a prospective cohort study |
| title_sort | incidence risk factors for active tuberculosis infection and changes of igra in patients with takayasu arteritis a prospective cohort study |
| topic | Takayasu arteritis tuberculosis standard incidence ratio risk factors interferon-γ release assay |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2024.2302099 |
| work_keys_str_mv | AT zhaopeng incidenceriskfactorsforactivetuberculosisinfectionandchangesofigrainpatientswithtakayasuarteritisaprospectivecohortstudy AT jingli incidenceriskfactorsforactivetuberculosisinfectionandchangesofigrainpatientswithtakayasuarteritisaprospectivecohortstudy AT zhanrong incidenceriskfactorsforactivetuberculosisinfectionandchangesofigrainpatientswithtakayasuarteritisaprospectivecohortstudy AT yangzhongzhou incidenceriskfactorsforactivetuberculosisinfectionandchangesofigrainpatientswithtakayasuarteritisaprospectivecohortstudy AT yanhongwang incidenceriskfactorsforactivetuberculosisinfectionandchangesofigrainpatientswithtakayasuarteritisaprospectivecohortstudy AT yingwang incidenceriskfactorsforactivetuberculosisinfectionandchangesofigrainpatientswithtakayasuarteritisaprospectivecohortstudy AT guizhizhang incidenceriskfactorsforactivetuberculosisinfectionandchangesofigrainpatientswithtakayasuarteritisaprospectivecohortstudy AT yunjiaoyang incidenceriskfactorsforactivetuberculosisinfectionandchangesofigrainpatientswithtakayasuarteritisaprospectivecohortstudy AT xinpingtian incidenceriskfactorsforactivetuberculosisinfectionandchangesofigrainpatientswithtakayasuarteritisaprospectivecohortstudy AT xiaofengzeng incidenceriskfactorsforactivetuberculosisinfectionandchangesofigrainpatientswithtakayasuarteritisaprospectivecohortstudy |